Literature DB >> 11686023

Clinical use of systemic IL-12 therapy.

J A Gollob1, J W Mier, M B Atkins.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11686023

Source DB:  PubMed          Journal:  Cancer Chemother Biol Response Modif        ISSN： 0921-4410


× No keyword cloud information.
  4 in total

1.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

Authors:  Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2011-02-01       Impact factor: 11.454

2.  Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.

Authors:  J M Péron; C Bureau; P Gourdy; H Lulka; A Souque; B Calippe; J Selves; T Al Saati; J Bernad; P Cordelier; B Couderc; L Pradayrol; B Pipy; L Buscail; J P Vinel
Journal:  Gut       Date:  2006-08-04       Impact factor: 23.059

3.  IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.

Authors:  Elizabeth W Sorensen; Scott A Gerber; John G Frelinger; Edith M Lord
Journal:  J Immunol       Date:  2010-01-08       Impact factor: 5.422

4.  Anti-Tumor Effects after Adoptive Transfer of IL-12 Transposon-Modified Murine Splenocytes in the OT-I-Melanoma Mouse Model.

Authors:  Daniel L Galvan; Richard T O'Neil; Aaron E Foster; Leslie Huye; Adham Bear; Cliona M Rooney; Matthew H Wilson
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.